Sai Parenterals Ltd (SAIPARENT) Q4FY26 Concall Summary - Mar-2026 Qtr
Performance Overview
- The company reported a transformational year in FY26, marked by a successful IPO and the strategic acquisition of Australia-based Noumed Pharmaceuticals, which significantly expanded its global IP-led platform.
- The acquisition of Noumed has shifted the company's business model from being manufacturing-led to an integrated global platform with capabilities spanning product development, manufacturing, regulatory filings, and last-mile commercialization.
- A strong focus on the CDMO export business was highlighted, with over 50% of consolidated revenue now originating from long-term supply contracts in regulated markets.
- The company is in a significant investment phase, executing a total capex program of INR 440 crores across India and Australia, aimed at capacity expansion, EU-GMP upgrades, and establishing a new R&D center. These investments are expected to drive growth from FY28 onwards.
- Management provided a positive outlook for FY27, targeting a consolidated revenue of INR 750 crores with an EBITDA margin of around 17%, driven by existing contracts, new dossier commercialization, and the full-year contribution from Noumed.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.